KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Globus Medical (GMED) Total Liabilities (2016 - 2025)

Globus Medical (GMED) has disclosed Total Liabilities for 15 consecutive years, with $729.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities fell 32.1% year-over-year to $729.5 million, compared with a TTM value of $729.5 million through Dec 2025, down 32.1%, and an annual FY2025 reading of $729.5 million, down 32.1% over the prior year.
  • Total Liabilities was $729.5 million for Q4 2025 at Globus Medical, up from $696.8 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $1.2 billion in Q3 2023 and bottomed at $174.9 million in Q1 2021.
  • Average Total Liabilities over 5 years is $560.4 million, with a median of $428.9 million recorded in 2023.
  • The sharpest move saw Total Liabilities soared 450.18% in 2023, then tumbled 38.99% in 2025.
  • Year by year, Total Liabilities stood at $215.9 million in 2021, then grew by 6.43% to $229.8 million in 2022, then skyrocketed by 373.61% to $1.1 billion in 2023, then dropped by 1.26% to $1.1 billion in 2024, then plummeted by 32.1% to $729.5 million in 2025.
  • Business Quant data shows Total Liabilities for GMED at $729.5 million in Q4 2025, $696.8 million in Q3 2025, and $665.4 million in Q2 2025.